Investor Relations

Mr. Wood has served as our President and Chief Executive Officer since September 2025 and a member of our board of directors since April 2024. He previously served as Corporate Vice President, Transcatheter Aortic Valve Replacement from February 2007 to September 2025, and as Group President for Surgical Structural Heart from 2023 to September 2025, at Edwards Lifesciences, a global leader in patient-focused medical innovations for structural heart disease and critical care and surgical monitoring. Mr. Wood has more than 35 years of experience in the medical technology industry at both Edwards Lifesciences and Baxter Healthcare Corporation in positions including manufacturing management, regulatory affairs and strategic and clinical marketing, primarily for the surgical heart valve therapy business. Mr. Wood received an M.B.A. from Pepperdine Graziadio Business School.

Ms. Rao has served as our EVP, Chief Strategy and Marketing Officer since November 2025. She previously served as Sr. Vice President, Marketing, Strategy, and Program Management from December 2023 to November 2025, and as Sr. Vice President, Strategy, Program Management, and Advanced Analytics from July 2022 until December 2023, at Edwards Lifesciences, a global leader in patient-focused medical innovations for structural heart disease and critical care and surgical monitoring. Prior to that, Ms. Rao served as Vice President, Strategy, Program Management, and Advanced Analytics from October 2021 until July 2022 and Sr. Director, Strategy, Program Management, and Advanced Analytics from November 2020 until October 2021, among other leadership positions after having started her career at Edwards Life Sciences in July 2007. Ms. Rao received a B.S. in Biomedical Engineering from University of Southern California.

Mr. McGill has served as our VP and General Manager, International since March 2020 and was promoted to SVP in September 2025. He is a globally recognized senior healthcare executive with more than 30 years of leadership across medical devices, life sciences, and digital health. Prior to joining PROCEPT BioRobotics, Mr. McGill held senior executive and corporate officer roles at AngioDynamics and American Medical Systems, where he consistently delivered accelerated revenue growth, expanded global market presence, and created substantial shareholder value. He has led multiple strategic acquisitions and successful exits of innovative technologies, with a combined transaction value exceeding $3.9 billion. Mr. McGill holds a C&G in Administration and Communication from Anniesland College and completed a leadership program at University of Minnesota Carlson School of Management.

Mr. Waters has served as our EVP, Chief Financial Officer since January 2022. He previously served as our SVP, Chief Financial Officer from October 2018 until December 2021. Prior to joining PROCEPT BioRobotics Mr. Waters served as Chief Financial Officer at Accuray Inc., a radiation oncology company, from September 2015 to October 2018. In addition to his experience at Accuray, Inc., Mr. Waters held financial leadership positions at three publicly traded medical device companies, including Conceptus, Laserscope and VISX. These companies were all sold to strategic acquirers, generating approximately $3 billion in shareholder value. Mr. Waters began his career at PricewaterhouseCoopers, LLP. and received a B.S. in Business Administration, with a double concentration in Accounting and Finance from Cal Poly San Luis Obispo.